CLINICAL_TRIALS
trial_result
· 2014-01-01
Clinical Trial Update: A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients [Phase 3]
Summary
The long-term Phase 3 safety and tolerability study of bapineuzumab in Alzheimer's disease was terminated, with results posted in 2014.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Alzheimer Disease | Phase 3 | Status: TERMINATED | Results posted: 2014-01-01